Onco-Innovations, a Canada-based company focused on cancer research and oncology treatment innovation, has announced that its wholly owned subsidiary, Inka Health has entered into a collaborative research agreement with GlaxoSmithKline LLC (GSK).

Under the agreement, Inka Health and GSK will work together to develop methodologies driven by real-world data to improve the transportability of oncology clinical trial outcomes across wider patient populations, geographical regions and healthcare environments. The initiative aims to make clinical evidence more applicable to real-world decision-making processes in oncology care.

As part of the collaboration, Inka Health will contribute its expertise in advanced analytics, including machine learning and causal inference methodologies, while working alongside GSK’s epidemiology and Real-World Evidence (RWE) specialists. The project will focus on developing conceptual and methodological frameworks for using real-world data to assess how clinical trial findings may translate into broader healthcare settings.

The research activities are expected to include a detailed review of existing transportability methodologies, development of a structured evaluation framework and retrospective validation using publicly available oncology datasets and use cases. The collaboration is also expected to result in jointly authored scientific publications involving researchers from both organisations.

The initiative addresses a key challenge in oncology research determining whether clinical trial outcomes observed in controlled patient groups can be effectively applied to broader and more diverse real-world populations. The project seeks to evaluate factors such as demographics, health conditions and healthcare access that may influence treatment outcomes across different settings.

GSK noted that the evolving use of real-world data has created increasing interest in methodologies that help assess the broader applicability of clinical evidence beyond traditional trial populations. The company believes the collaboration can contribute to scientific advancements in oncology evidence generation and support more rigorous approaches to evaluating treatment effectiveness in real-world contexts.

Onco-Innovations stated that the collaboration reflects the growing importance of advanced analytics and evidence-generation capabilities in shaping the future of oncology research. The company added that the project aligns with its broader vision of building integrated oncology innovation platforms and supporting smarter drug development pathways, including future investigational new drug (IND)-enabling activities.

Onco-Innovations continues to focus on advancing cancer prevention and treatment through innovative research, data-driven technologies and scientific collaboration in oncology.